Inspire Medical Systems, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Rhea-AI Summary
Inspire Medical Systems (NYSE: INSP) will report fourth quarter and full year 2025 financial results after market close on Wednesday, February 11, 2026. Management will host a conference call at 5:00 p.m. Eastern Time to discuss results and recent business developments.
A live webcast will be available on the company’s Investor Relations page and registration is required to ask questions; registrants receive dial-in details and a unique access code. The company recommends registering at least 10 minutes before the call. A replay will be posted approximately two hours after the event and archived on the Investor Relations site for two weeks.
Positive
- None.
Negative
- None.
News Market Reaction – INSP
In the Jan 7 session, INSP gained 1.87%, reflecting a mild positive market reaction. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 29 | Conference presentation | Neutral | -1.9% | J.P. Morgan Healthcare Conference presentation and webcast details. |
| Nov 18 | Conference presentation | Neutral | -1.5% | Piper Sandler healthcare conference participation with webcast access. |
| Nov 03 | Earnings release | Positive | +2.3% | Q3 2025 earnings with revenue growth and raised EPS guidance. |
| Oct 27 | Conference presentation | Neutral | +0.9% | UBS Global Healthcare Conference presentation and webcast replay. |
| Oct 10 | Clinical data update | Positive | -6.2% | Inspire V clinical and market data with improved outcomes and safety. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent conference and news events have shown mixed reactions, while the last earnings report saw a modest positive move; a major clinical data update drew a negative reaction despite positive metrics.
Over the last few months, INSP has reported several investor-focused events and operational updates. An Oct 10, 2025 clinical data release for Inspire V featured strong efficacy and safety yet coincided with a -6.2% move. The Q3 2025 earnings on Nov 3 showed revenue of $224.5M and reaffirmed full-year guidance, with shares up 2.26%. Subsequent conference announcements in late 2025 produced small negative to modestly positive reactions. Today’s earnings-date notice fits this pattern of informational, lower-impact disclosures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the fourth quarter and full year 2025 after the close of trading on Wednesday, February 11. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.
A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q4 2025 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.
If you plan to ask a question, please use the following link: Inspire's Q4 2025 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.
Following the call, a replay will be available on the Company's Investor Relations website approximately two hours after the event and archived on the site for two weeks.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443
